Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPER RCC: Perioperative Nivolumab vs Observation in Renal Cell Carcinoma
NCT03055013Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2017
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of nivolumab in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Apr 2017; status: active, not recruiting.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03055013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03055013.